As the popularity of weight loss drugs like Ozempic continues to climb, a disturbing pattern is emerging — and it's impacting ...

Novo Nordisk (NVO) presented results from STRIDE, its phase 3b trial investigating the effects of once-weekly Ozempic injection 1 mg in adults ...

Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...

As a federal crackdown on Ozempic-style copycats looms, Hims is trying a unique new strategy to lobby lawmakers.

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Wegovy was also associated with a lower risk of hospitalization for heart failure, cardiovascular-related death, and ...

New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...